Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company ...